FDA DEVICE FACTS
OneTouch Vibe™ Plus System
Animas Corp.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
The OneTouch Vibe™ Plus System consists of the Animas® Vibe® Insulin Pump paired with the Dexcom G5® Sensor and Transmitter.
The OneTouch Vibe™ Plus System is indicated for continuous subcutaneous insulin infusion for the management of insulin-requiring diabetes. It can be used solely for continuous insulin delivery and as part of the OneTouch Vibe™ Plus System to receive and display continuous glucose measurements from the Dexcom G5® Sensor and Transmitter.
The OneTouch Vibe™ Plus System's continuous glucose monitoring (CGM) is indicated for detecting trends and tracking patterns in persons (ages 2 and older) with diabetes, and is intended to complement, not replace, information obtained from standard home
PMA P130007.S016: FDA Summary of Safety and Effectiveness Data Page 2
glucose monitoring devices. CGM aids in the detection of episodes of hyperglycemia and hypoglycemia , facilitating both acute and long-term therapy adjustments, which may minimize these excursions. Interpretation of results from the Dexcom G5® Sensor and Transmitter should be based on the trends and patterns seen with several sequential readings over time.
The System is intended for single patient use and requires a prescription.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。